GridAI Technologies Corp (GRDX) is an energy software company that develops AI-enabled software and services designed to accelerate power availability and optimize energy infrastructure for AI data centers and other large energy users. The company is in the development stage and generates no material revenue from its core platform as of the 10-K filed 2026-05-01. GridAI Technologies Corp is the renamed successor to Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.), which operated as a clinical-stage biopharmaceutical company before acquiring Grid AI Corp. on September 30, 2025. The company also retains a legacy biopharmaceutical asset, Adrulipase, a recombinant lipase enzyme in development for exocrine pancreatic insufficiency. Grid AI Corp. itself acquired AMPX in February 2025, inheriting two prior technology platforms, DLS and ALICE Home Energy Management Systems, both scaled back to minimum support levels following a 2025 strategic pivot toward energy orchestration for hyperscale AI data center campuses.

Revenue model

The company generates no material revenue from its AI data center platform as of the 10-K filed 2026-05-01. Commercial pipeline activity is consulting-led, with ongoing business development discussions primarily involving battery energy storage system providers. Prior trial deployments, including in Australia, have not produced significant commercial revenue.

Products and services

Grid AI Corp.'s primary development-stage product is an AI data center energy orchestration platform that aims to optimize distributed energy resources, including battery energy storage systems, on-site generation, and grid interconnections. The company also supports two legacy platforms acquired via AMPX in February 2025: DLS developed technology and ALICE Home Energy Management Systems (HEMS), both maintained at minimum support levels as of the 2025 strategic pivot. The legacy biopharmaceutical pipeline includes Adrulipase, a recombinant lipase enzyme targeting exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.

Customers and end markets

The company has no major customers as of the 10-K filed 2026-05-01. Current business development discussions are primarily with battery energy storage system providers and energy infrastructure participants, including Mango Power and Nomad Transportable Power Systems. Target end markets include hyperscale AI data center campuses and large energy users.

Value-chain role

Grid AI Corp. operates as a software and services provider in the energy management stack, sitting between distributed energy resource hardware providers and data center operators. It does not manufacture hardware. The legacy biopharmaceutical segment is a clinical-stage drug developer holding patents on lipase production methods and Adrulipase formulations.

Geographic exposure

The company is evaluating opportunities across the United States, United Kingdom, and Australia, where prior trial deployments have been conducted. Market prioritization is ongoing based on adoption dynamics by geography, per the 10-K filed 2026-05-01.

Source: SEC 10-K, filed 2026-05-01

Industry: Electric & Other Services Combined Peers: ACTAVIA LIFE SCIENCES, INC. Allena Pharmaceuticals, Inc. GlobeStar Therapeutics Corp International Stem Cell Corp Endonovo Therapeutics Inc Innoveren Scientific, Inc. PREMIER BIOMEDICAL INC